Sign in

SRTS on Nasdaq

Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is an American surgical and medical instruments and apparatus company.2 It is headquartered in Boca Raton, United States.2 Its shares trade on Nasdaq under the symbol SRTS.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with MELA Sciences, Premier Air Charter Holdings Inc. or Orchestra BioMed Holdings, Inc., or pick any stock.

  • TickerSRTS on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersBoca Raton, United States2
  • Incorporated inDE3
  • Business address851 Broken Sound Parkway Nw, Suite 215, Boca Raton, Fl 334873
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300F3JF8NCDJJZW042
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATE CREATIONS NETWORK INC., 19803 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 48207692

See how the biggest companies compare on our leaderboards

As of December 31, 2025, the Company had installed 955 units in 21 countries, primarily in the United States.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

43.2%Gross margin5
-37.5%Operating margin5
-28.1%Net margin5
-34.3%Revenue growth, 20255
-16.0%Return on equity5
$332.0KFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 72% of the revenue Sensus Healthcare, Inc. broke down this way in fiscal 2025.

  1. Product$19.8M572%down 46% from 2024
  2. Service Revenue$3.5M513%up 8% from 2024
  3. Service$2.5M59%up 30% from 2024
  4. Product Revenue$1.7M56%up 597% from 2024
Products and services by year
Products and services20242025
Product$36.4M$19.8M
Service Revenue$3.2M$3.5M
Service$2.0M$2.5M
Product Revenue$247.0K$1.7M

Regions

United States brought in 92% of the revenue Sensus Healthcare, Inc. broke down this way in fiscal 2025.

  1. United States$25.4M592%down 37% from 2024
  2. [Canada]$2.0M57%up 40% from 2024
  3. Other$90.0K50%down 51% from 2024
Regions by year
Regions20242025
United States$40.2M$25.4M
[Canada]$1.4M$2.0M
Other$182.0K$90.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue47¢$15.6M
  • Research and development23¢$7.8M
  • Selling, general and admin24¢$7.9M
  • Income tax6¢$1.9M

Out of $27.5M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending37¢$196.0K
  • Share buybacks57¢$300.0K
  • Kept or used elsewhere6¢$32.0K

Out of $528.0K of cash from operations.5

Financial statements

Revenue6789105$27.5M in 2025+1% since 2019
0$20.0M$40.0M$60.0M2019: $27.3M$27.3M20192020: $9.6M$9.6M2020−65%2021: $27.0M$27.0M2021+182%2022: $44.5M$44.5M2022+65%2023: $24.4M$24.4M2023−45%2024: $41.8M$41.8M2024+71%2025: $27.5M$27.5M2025−34%
Gross profit6789105$11.9M in 2025−32% since 2019
0$10.0M$20.0M$30.0M2019: $17.6M$17.6M20192020: $5.2M$5.2M2020−70%2021: $17.0M$17.0M2021+224%2022: $29.6M$29.6M2022+74%2023: $14.1M$14.1M2023−53%2024: $24.4M$24.4M2024+74%2025: $11.9M$11.9M2025−51%
Operating income6789105-$10.3M in 2025+424% since 2019
-$20.0M-$10.0M0$10.0M$20.0M2019: -$2.0M-$2.0M20192020: -$8.2M-$8.2M2020+318%2021: $4.1M$4.1M20212022: $14.8M$14.8M2022+260%2023: -$382.0K-$382.0K20232024: $8.1M$8.1M20242025: -$10.3M-$10.3M2025
Net income6789105-$7.7M in 2025+354% since 2019
-$10.0M0$10.0M$20.0M$30.0M2019: -$1.7M-$1.7M20192020: -$6.8M-$6.8M2020+302%2021: $4.1M$4.1M20212022: $24.2M$24.2M2022+489%2023: $485.0K$485.0K2023−98%2024: $6.6M$6.6M2024+1271%2025: -$7.7M-$7.7M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenues$27.5M$41.8M
Cost of sales$15.6M$17.4M
Gross profit$11.9M$24.4M
General and administrative$7.9M$7.1M
Selling and marketing$6.5M$5.0M
Research and development$7.8M$4.2M
Total operating expenses$22.2M$16.3M
(Loss) income from operations-$10.3M$8.1M
Interest income, net$683.0K$932.0K
Other income, net$683.0K$932.0K
(Loss) income before income taxes-$9.6M$9.0M
(Benefit from) provision for income taxes-$1.9M$2.4M
Net (loss) income-$7.7M$6.6M
Net (loss) income per share - basic-$0.47$0.41
Net (loss) income per share - diluted-$0.47$0.41
Weighted average number of shares used in computing net (loss) income per share - basic16.3M shares16.3M shares
Weighted average number of shares used in computing net (loss) income per share - diluted16.3M shares16.4M shares

Compare Sensus Healthcare, Inc. with another company

Corporate structure

Sensus Healthcare, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sensus Healthcare, Inc.

  • Joseph C. Sardano Filed SCHEDULE 13G/A on Sensus Healthcare, Inc., latest May 22, 2025
  • Edwin Lee Solot Filed SCHEDULE 13G/A on Sensus Healthcare, Inc., latest Feb 7, 2025 (4 filings since Feb 7, 2022)
  • Sensus Healthcare, Inc. Boca Raton, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sensus Healthcare, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$228.0K5 Dec 31, 2025$228.0K5 Dec 31, 20240%
Property and equipment, before depreciation$4.2M5 Dec 31, 2025$3.9M5 Dec 31, 2024+7.7%
Accumulated depreciation$2.1M10 Dec 31, 2024$1.9M10 Dec 31, 2023+12.6%
Property and equipment, net$2.0M5 Dec 31, 2025$2.0M5 Dec 31, 2024−1.1%
Operating-lease assets (leased space)$452.0K5 Dec 31, 2025$581.0K5 Dec 31, 2024−22.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$22.1M5 Dec 31, 2025$22.1M5 Dec 31, 2024+0.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$14.6M5 Dec 31, 2025$10.1M5 Dec 31, 2024+44.2%

Properties, in its own words

The Company’s corporate headquarters is located in Boca Raton, Florida and occupies a total of 10,356 square feet of space under a lease and a sublease that both expire in September 2027. The Company believes that the current facilities are suitable and adequate to meet the Company’s current needs and that suitable additional space will be available as and when needed. The Company’s main manufacturing function is physically located at our third-party manufacturer’s facility in Oak Ridge, Tennessee. Additional disclosures have been included within Note 6, Commitments and Contingencies, of the consolidated financial statements.

Item 2 of the 10-K filed Mar 4, 2026.4

Leadership

Who has led Sensus Healthcare, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joseph C. Sardano2016–now

President

  1. Michael Sardano2022–now

Chief financial officer

  1. Javier Rampolla2020–now

Chief operating officer

  1. Nicolas Soro2020–2022
  2. Magdalena Martinez2023–now
20202025
Board members and other officers (17)

Former names

  • Sensus Healthcare, LLCJul 2, 2010 to Dec 30, 20153

Timeline

  1. Aug 13, 20268-K Results of operations34
  2. Jun 5, 20268-K Entered a material agreement35
  3. Jun 2, 20268-K Shareholder vote36
  4. May 7, 20268-K Results of operations37
  5. Feb 12, 20268-K Results of operations38
  6. Jan 20, 20268-K Change of auditor39
  7. Jan 12, 20268-K Executive or director change40
  8. Nov 13, 20258-K Executive or director change41
  9. Nov 6, 20258-K Results of operations42
  10. Aug 7, 20258-K Results of operations43
  11. Jun 2, 20258-K Shareholder vote44
  12. May 15, 20258-K Results of operations45
  13. Jun 2, 2016New chief executive Joseph C. Sardano becomes CEO13
  14. May 7, 2010Founded Sensus Healthcare, Inc. is founded2

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/202646

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results34
  2. May 7, 2026Reported quarterly or annual results37
  3. Feb 12, 2026Reported quarterly or annual results38
  4. Nov 6, 2025Reported quarterly or annual results42
  5. Aug 7, 2025Reported quarterly or annual results43
  6. May 15, 2025Reported quarterly or annual results45
  7. Feb 5, 2025Reported quarterly or annual results47
  8. Nov 18, 2024Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

150 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 42 major events, 71 insider forms, 5 large holders, 12 other. The latest 20:

  1. Aug 31, 20264 EDGAR
  2. Aug 28, 20264 EDGAR
  3. Aug 25, 20264 EDGAR
  4. Aug 24, 20264 EDGAR
  5. Aug 24, 20264 EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 13, 20268-K EDGAR
  8. Jun 5, 20268-K EDGAR
  9. Jun 2, 20268-K EDGAR
  10. May 18, 2026SD EDGAR
  11. May 13, 202610-Q EDGAR
  12. May 12, 20264 EDGAR
  13. May 7, 20268-K EDGAR
  14. Apr 29, 2026DEF 14A EDGAR
  15. Apr 23, 20264/A EDGAR
  16. Apr 22, 20263/A EDGAR
  17. Apr 22, 20264/A EDGAR
  18. Apr 22, 20264/A EDGAR
  19. Mar 4, 202610-K EDGAR
  20. Feb 26, 20264 EDGAR

The 150 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

65 open-market trades by officers, directors and large owners since October 2021: 30 buys and 35 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Sachetta EricDirectorBuy27,304$3.54$96.7KForm 4
Aug 28, 2026Sachetta EricDirectorBuy37,537$3.44$129.1KForm 4
Aug 27, 2026Sachetta EricDirectorBuy10,925$3.18$34.7KForm 4
Aug 26, 2026Sachetta EricDirectorBuy9,708$3.29$31.9KForm 4
Aug 24, 2026Sachetta EricDirectorBuy34,697$3.25$112.8KForm 4
Aug 21, 2026Sachetta EricDirectorBuy7,000$3.25$22.8KForm 4
Aug 20, 2026Sachetta EricDirectorBuy24,000$3.13$75.1KForm 4
Aug 20, 2026Sardano Joseph CCHIEF EXECUTIVE OFFICERBuy20,000$3.02$60.4KForm 4
May 12, 2026Sachetta EricDirectorBuy1,500$3.34$5.0KForm 4
Feb 24, 2026Sachetta EricDirectorBuy2,000$3.81$7.6KForm 4
Nov 21, 2025Sachetta EricDirectorBuy7,000$3.93$27.5KForm 4
Nov 18, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy1,000$3.80$3.8KForm 4
Nov 18, 2025Sardano Joseph CCHIEF EXECUTIVE OFFICERBuy25,000$4.03$100.8KForm 4
Nov 13, 2025Sachetta EricDirectorBuy2,500$4.50$11.2KForm 4
Nov 11, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy2,000$4.27$8.5KForm 4
Nov 11, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy2,000$4.26$8.5KForm 4
Nov 11, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy1,000$4.26$4.3KForm 4
Aug 13, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy1,000$3.37$3.4KForm 4
Feb 10, 2025Rampolla JavierCHIEF FINANCIAL OFFICERBuy501$5.95$3.0KForm 4
Feb 10, 2025Sardano MichaelPRESIDENT AND GENERAL COUNSELBuy1,000$5.95$6.0KForm 4

All 65 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Joseph C. SardanoSCHEDULE 13G/A, 1 filing May 22, 202549
  • Edwin Lee SolotSCHEDULE 13G/A, 4 filings Feb 7, 2022 to Feb 7, 202550

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Joseph C. Sardano73$600.0K$1.4M51
2025Michael Sardano38$500.0K$1.2M51
2025Javier Rampolla54$400.0K$752.7K51
2024President, GeneralCounsel, Chief Commercial Officer, & Corporate Secretary$350.0K$1.3M51
2024Chief Executive Officer$500.0K$1.3M51
2024Chief Financial Officer$300.0K$656.0K51

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 38. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Pacific Ridge Capital Partners, LLC789,675$2.4M0.4%−6,397
Vanguard Capital Management LLC660,402$2.0M0.0%+12,177
Dimensional Fund Advisors LP316,121$954.8K0.0%−71,271
Divisadero Street Capital Management, LP278,485$841.0K0.0%−7,593
Renaissance Technologies LLC242,334$731.8K0.0%−9,900
Geode Capital Management, LLC154,152$465.7K0.0%−11,398
UBS Group AG152,573$460.8K0.0%−20,297
Sachetta, LLC152,008$459.1K0.2%+1,500
Greenline Wealth Management LLC128,774$388.9K0.3%No change
North Star Investment Management Corp.125,586$379.3K0.0%No change
Bank of New York Mellon Corp100,410$303.2K0.0%No change
BlackRock, Inc.83,555$252.3K0.0%+12,388
Vanguard Fiduciary Trust Co76,289$230.4K0.0%+559
State Street Corp69,252$209.1K0.0%No change
Mindset Wealth Management, LLC52,100$157.3K0.0%No change
Northern Trust Corp28,187$85.1K0.0%−40,006
Chapin Davis, Inc.26,000$78.5K0.0%No change
American Century Companies Inc21,272$64.2K0.0%No change
Ashton Thomas Private Wealth, LLC16,307$49.2K0.0%+639
EP Wealth Advisors, LLC16,065$48.5K0.0%New
StoneX Group Inc.13,378$47.9K0.0%New
Jane Street Group, LLC12,518$37.8K0.0%−9,834
XTX Topco Ltd12,178$36.8K0.0%New
Rockefeller Capital Management L.P.7,000$21.1K0.0%No change
Vanguard Global Advisers, LLC4,961$15.0K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sensus Healthcare, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSensus Healthcare, Inc.1
  • CIK0001494891
  • Employer ID (EIN)27-16472714
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address851 Broken Sound Parkway Nw, Suite 215, Boca Raton, FL 334871
  • Phone561-922-58081
  • Shares outstanding16,462,059 as of Aug 10, 202612
  • Public float$70.9M as of Jun 30, 20254
  • AuditorBerkowitz Pollack Brant, Advisors + CPAs, West Palm Beach, FL PCAOB ID 524
  • On EDGAR sinceJul 2, 20101
  • Filings407 in all: 4 (158), 8-K (82), 10-Q (31), 3 (21), 4/A (12), SC 13G (11), 10-K (10), CORRESP (10)1
    All 39 form types

    DEF 14A (10), SD (6), 5 (5), D (4), S-1/A (4), S-8 (4), DEFA14A (3), SC 13G/A (3), UPLOAD (3), 25-NSE (2), 3/A (2), CERTNAS (2), CT ORDER (2), EFFECT (2), FWP (2), PRE 14A (2), SCHEDULE 13G/A (2), 10-K/A (1), 424B2 (1), 424B3 (1), 424B4 (1), 424B5 (1), 8-A12B (1), 8-A12B/A (1), D/A (1), DEFR14A (1), DRS (1), DRSLTR (1), S-1 (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 4, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Aug 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01 per shareSRTSNASDAQ

From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Sensus Healthcare, Inc. names in Item 1A of its 10-K filed Mar 4, 2026: 24 risks under these headings, as written.4

  • Risks Related to our Business
  • If third-party payors do not provide coverage and adequate reimbursement for the use of our products, it is unlikely that our products will be widely used, and our revenue will be negatively impacted.
  • Substantially all of the Company’s revenue is generated from the sale of the SRT-100 and related products, and any decline in the sales of these products will negatively impact the Company’s business, financial condition, and results of operations.
  • The Company’s technology could be superseded by new products, treatments, or technologies that gain wider acceptance among doctors and patients, which could adversely affect the Company.
  • The Company’s customers, including one U.S. customer accounting for a significant portion of our sales, are concentrated in the U.S., and economic difficulties or changes in the purchasing policies or patterns of the Company’s customers in the U.S. has had and could have in the future a significant impact on our business and operating results.
  • The Company has a single preferred supplier for the x-ray tubes and other major components used in the Company’s products and the loss of this preferred supplier could adversely affect the Company.
  • The Company’s operations may be impaired if our information technology systems fail to perform adequately or are the subject of a data breach or cyberattack.
  • Sensus may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all.
  • Consolidation in the healthcare industry could adversely affect the Company’s future revenues and operating income.
  • Pandemics, natural disasters, global climate change, acts of terrorism and global conflicts may have a negative impact on our business and operations.
  • Risks Related to our Regulatory Environment
  • Sensus is subject to various federal, state, and foreign healthcare laws and regulations, and a finding of failure to comply with these laws and regulations could have a material adverse effect on its business.
The other 14 risks
  • Sensus is required to comply with medical device reporting requirements and must report certain malfunctions, deaths, and serious injuries associated with its products, which can result in voluntary corrective actions or agency enforcement actions.
  • Healthcare policy changes may have a material adverse effect on Sensus’s business.
  • Risks Related to our Intellectual Property
  • If Sensus’s patents and other intellectual property rights do not adequately protect its products, it may lose market share to competitors and be unable to operate business profitably.
  • If Sensus’s trademarks or trade names are not adequately protected, then Sensus may be unable to build name recognition in markets of interest and its business may be adversely affected.
  • The medical device industry is characterized by extensive patent litigation, and if Sensus becomes subject to litigation, it could be costly, result in the diversion of management’s attention, require us to pay significant damages or royalty payments, or prevent us from marketing and selling existing or future products.
  • Adverse outcomes in litigation or similar proceedings could adversely impact business.
  • Risks Related to the Ownership of Sensus’s Securities
  • We have a history of net losses prior to 2021 and we reported a net loss in 2025. If we do not return to and maintain profitability, our financial condition and the value of our common stock could suffer.
  • Limited trading activity for shares of Sensus’s common stock may contribute to price volatility.
  • The Company does not anticipate paying dividends for the foreseeable future. As a result, investors must rely on price appreciation of the Company’s common stock for a return on its investment in the foreseeable future.
  • Sensus’s executive officers and directors may exert control over the Company and may exercise influence over matters subject to stockholder approval.
  • If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about Sensus, the price of Sensus’s securities and trading volume could decline.
  • The Company’s certificate of incorporation and bylaws, and Delaware law contain provisions that could discourage another company from acquiring the Company and may prevent attempts by the Company’s stockholders to replace or remove the current directors and management.
  • The Company’s certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the Company and its stockholders, which could limit a stockholder’s ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers, or employees.
  • If the Company fails to maintain proper and effective internal controls, the Company’s ability to produce accurate and timely financial statements could be impaired and investors’ views of the Company or its business could be harmed, resulting in a decrease in value of the Company’s common stock.

Legal proceedings

From time to time, Sensus is party to certain legal proceedings in the ordinary course of business. Management, after consultation with legal counsel, currently does not anticipate that the aggregate liability arising out of these legal proceedings will have a material effect on Sensus’s results of operations, financial position, or cash flows and have assessed that there is no need to record a liability for these legal proceedings and related contingencies. Additional disclosures have been included within Note 6, Commitments and Contingencies, of the consolidated financial statements.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51